Rewriting a Cholesterol-Lowering Drug's Warning Label? (IMAGE)

American Association for the Advancement of Science (AAAS)

Rewriting a Cholesterol-Lowering Drug's Warning Label?

Caption

A new study finds that a clinically approved cholesterol-lowering drug may be less toxic to the liver than previously thought. This material relates to a paper that appeared in the Jan. 27, 2016 issue of Science Translational Medicine, published by AAAS. The paper, by G. Reyes-Soffer at Columbia University College of Physicians and Surgeons in New York, NY, and colleagues was titled, "Complex effects of inhibiting hepatic apolipoprotein B100 synthesis in humans."

Credit

Val Altounian / <i>Science Translational Medicine</i>

Usage Restrictions

Please cite the owner of the material when publishing. This material may be freely used by reporters as part of news coverage, with proper attribution. Non-reporters must contact <i>Science</i> for permission.

License

Licensed content

Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.